What is the best targeted drug for advanced gastric cancer? Is ramucirumab Cyramab available in Chin

Overall survival in patients with advanced gastric or GEJ adenocarcinoma who received paclitaxel + ramucirumab versus paclitaxel as a second-line ** after failure of platinum and fluorouracil combinations** (with or without anthracyclines [epirubicin or doxorubicin]).

1. Experimental theme.

A phase III randomized, double-blind, multicenter study of ramucirumab + paclitaxel versus paclitaxel in patients with advanced gastric or GEJ adenocarcinoma in the second line** (after failure of platinum and fluorouracil in combination** with or without anthracyclines [epirubicin or doxorubicin]).

2. Indications.

Adenocarcinoma of the stomach or gastroesophageal junction.

Third, the purpose of the test.

To investigate overall survival in patients with advanced gastric or GEJ adenocarcinoma with ramucirumab + paclitaxel versus paclitaxel as a second-line (after failure of platinum and fluorouracil in combination** with or without anthracyclines [epirubicin or doxorubicin]).

5.Inoperable or metastatic disease, prior first-line regimen of platinum-containing drugs in combination with fluorouracil** (platinum-based agents include cisplatin, carboplatin, or oxaliplatin; Fluorouracil includes 5-FU, capecitabine, or S-1) with or without an anthracycline (epirubicin or doxorubicin). The patient has documented clear radiographic or symptomatic disease progression (eg, any new or malignant pleural effusion on ultrasound) during the first-line** period or within 4 months of the last dose, and the diagnosis can be confirmed by pathologic diagnostic criteria (histology or cytology) when appropriate.

6. Exclusion Criteria.

1.Have squamous cell carcinoma or undifferentiated gastric cancer;

2.Has received any first-line chemotherapy other than platinum and fluorouracil with or without anthracyclines**Advanced gastric or GEJ adenocarcinoma;

3.Prior receipt of the following systemic chemotherapy: epirubicin cumulative dose (900 mg m2) or doxorubicin (400 mg m2);

4.Prior receipt of any systemic ** targeting VEGF or VEGFR signaling pathways. Prior receipt of other types of targeting** is permitted, but it is required to be discontinued at least 28 days prior to randomization**;

5.Being receiving anticoagulation with warfarin, low molecular weight heparin, or equivalent**. Patients receiving prophylactic low-dose anticoagulation** may be eligible to participate in the study, but only if the anticoagulation parameters specified in the inclusion criteria (INR;

6.Ongoing treatment with non-steroidal anti-inflammatory drugs or other antiplatelet agents**. However, aspirin (acetylsalicylic acid) at a dose of 325 mg a day or less is allowed;

7.Have symptomatic congestive heart failure or have symptomatic or poorly controlled arrhythmias;

8.Has intestinal obstruction, has or has a history of the following: inflammatory bowel disease or extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea.

Rademolumab is a humanized IgG-1 monoclonal antibody with high affinity for VEGFR-2 that blocks VEGF activation. CYR is a drug used in patients whose cancer is not resectable (unresectable) and in which the tumor has spread and metastasized after fluoropyrimidine or platinum. My friend was diagnosed with stomach cancer and needed ramucirumab.

There are no hospitals in the mainland, and they went to Xianggang through Hong Kong Adventist Health Doctor to use the drug.

Ramucirumab was approved by the FDA on April 21, 2014 for the treatment of **gastric cancer or gastroesophageal junction adenocarcinoma, metastatic non-small cell lung cancer and colorectal cancer. It is recommended to see an oncologist first, and the doctor will make a judgment and guide on the medication.

Ramucirumab cyramza is indicated for patients with unresectable cancer (unresectable) and for patients with gastric cancer whose tumors have spread ** after fluoropyrimidine or platinum drugs**, and has been shown to prolong the survival of patients with advanced gastric cancer and liver cancer. If patients want to buy the drug, they can consult Adventist Health.

This can be queried in Hong Kong Jimin Pharmaceutical, every time I want to find information related to this drug, it is also found in Hong Kong Jimin Pharmaceutical, and the latest information about this drug will often be updated here, you can collect it, I will copy this content to you first:

What is the possible *** of Cyramza?

Seek emergency medical help if you have signs of an allergic reaction to cyramza: hives, difficulty breathing, swelling of the face, lips, tongue or throat.

Tell your doctor immediately if you experience dizziness, chills, sweating, or chest pain, chest tightness, back pain, difficulty breathing, or numbness and tingling.

Cyramza increases your risk of severe bleeding.

Signs of gastric bleeding – severe stomach pain, blood in the stool or tarry stools, coughing up blood or vomit;

Any wound that does not heal;

headache, confusion, altered mental status, loss of vision, seizures (convulsions);

severe or persistent nausea, vomiting, or diarrhea;

Rapid weight gain, especially on the face and abdomen;

Low white blood cell count – fever, mouth ulcers, **ulcers, sore throat, cough, difficulty breathing;

Kidney problems – puffy eyes, swollen ankles or feet, weight gain, urine that looks blistered;

Symptoms of blood clots – sudden numbness or weakness (especially on one side of the body), sudden severe headache, slurred speech, problems with vision or balance;

Heart attack symptoms – chest pain or pressure, pain spreading to the jaw or shoulders, nausea, sweating.